Kindred Biosciences Stock Price, News & Analysis (NASDAQ:KIN)

$8.60 +0.10 (+1.18 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$8.60
Today's Range$8.40 - $8.60
52-Week Range$5.20 - $9.80
Volume25,725 shs
Average Volume62,219 shs
Market Capitalization$239.55 million
P/E Ratio-7.35
Dividend YieldN/A
Beta0.07

About Kindred Biosciences (NASDAQ:KIN)

Kindred Biosciences logoKindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company's lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company's other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.

Receive KIN News and Ratings via Email

Sign-up to receive the latest news and ratings for KIN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KIN
CUSIPN/A
Phone650-701-7901

Debt

Debt-to-Equity RatioN/A
Current Ratio24.02%
Quick Ratio24.02%

Price-To-Earnings

Trailing P/E Ratio-7.35042735042735
Forward P/E Ratio-7.23
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.90 per share
Price / Book2.97

Profitability

Trailing EPS($1.17)
Net Income$-22,490,000.00
Net MarginsN/A
Return on Equity-36.18%
Return on Assets-34.66%

Miscellaneous

Employees41
Outstanding Shares28,180,000

Kindred Biosciences (NASDAQ:KIN) Frequently Asked Questions

What is Kindred Biosciences' stock symbol?

Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."

How were Kindred Biosciences' earnings last quarter?

Kindred Biosciences Inc (NASDAQ:KIN) released its earnings results on Tuesday, November, 7th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping analysts' consensus estimates of ($0.33) by $0.04. View Kindred Biosciences' Earnings History.

When will Kindred Biosciences make its next earnings announcement?

Kindred Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, February, 27th 2018. View Earnings Estimates for Kindred Biosciences.

Where is Kindred Biosciences' stock going? Where will Kindred Biosciences' stock price be in 2018?

6 equities research analysts have issued twelve-month price objectives for Kindred Biosciences' stock. Their predictions range from $8.00 to $11.00. On average, they expect Kindred Biosciences' share price to reach $9.90 in the next year. View Analyst Ratings for Kindred Biosciences.

Who are some of Kindred Biosciences' key competitors?

Who are Kindred Biosciences' key executives?

Kindred Biosciences' management team includes the folowing people:

  • Wendy Wee, Chief Financial Officer (Age 64)
  • Denise M. Bevers, Chief Operating Officer, Secretary (Age 47)
  • Hangjun Zhan, Chief Scientific Officer
  • Herbert D. Montgomery, Independent Director (Age 68)
  • Raymond Townsend, Independent Director (Age 70)
  • Ervin Veszpremi, Independent Director (Age 56)

Who owns Kindred Biosciences stock?

Kindred Biosciences' stock is owned by many different of retail and institutional investors. Top institutional investors include Ariel Investments LLC (6.94%), BlackRock Inc. (3.96%), Renaissance Technologies LLC (2.58%), General American Investors Co. Inc. (2.23%), Wells Fargo & Company MN (1.30%) and Deutsche Bank AG (0.49%). Company insiders that own Kindred Biosciences stock include Ernest Mario, Park West Asset Management Llc, Raymond Townsend and Richard Chin. View Institutional Ownership Trends for Kindred Biosciences.

Who sold Kindred Biosciences stock? Who is selling Kindred Biosciences stock?

Kindred Biosciences' stock was sold by a variety of institutional investors in the last quarter, including Ariel Investments LLC, Renaissance Technologies LLC, Deutsche Bank AG, General American Investors Co. Inc., C M Bidwell & Associates Ltd. and Wolverine Trading LLC. Company insiders that have sold Kindred Biosciences company stock in the last year include Raymond Townsend and Richard Chin. View Insider Buying and Selling for Kindred Biosciences.

Who bought Kindred Biosciences stock? Who is buying Kindred Biosciences stock?

Kindred Biosciences' stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Wells Fargo & Company MN, Bank of New York Mellon Corp and Schwab Charles Investment Management Inc.. Company insiders that have bought Kindred Biosciences stock in the last two years include Ernest Mario and Park West Asset Management Llc. View Insider Buying and Selling for Kindred Biosciences.

How do I buy Kindred Biosciences stock?

Shares of Kindred Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kindred Biosciences' stock price today?

One share of Kindred Biosciences stock can currently be purchased for approximately $8.60.

How big of a company is Kindred Biosciences?

Kindred Biosciences has a market capitalization of $239.55 million. The biopharmaceutical company earns $-22,490,000.00 in net income (profit) each year or ($1.17) on an earnings per share basis. Kindred Biosciences employs 41 workers across the globe.

How can I contact Kindred Biosciences?

Kindred Biosciences' mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The biopharmaceutical company can be reached via phone at 650-701-7901 or via email at [email protected]


MarketBeat Community Rating for Kindred Biosciences (KIN)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  147 (Vote Outperform)
Underperform Votes:  152 (Vote Underperform)
Total Votes:  299
MarketBeat's community ratings are surveys of what our community members think about Kindred Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Kindred Biosciences (NASDAQ:KIN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.673.003.00
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $9.90$9.90$9.80$9.00
Price Target Upside: 3.13% upside3.13% upside33.33% upside29.50% upside

Kindred Biosciences (NASDAQ:KIN) Consensus Price Target History

Price Target History for Kindred Biosciences (NASDAQ:KIN)

Kindred Biosciences (NASDAQ:KIN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/27/2017CL KingInitiated CoverageNeutral -> NeutralLowView Rating Details
12/22/2017BMO Capital MarketsReiterated RatingHoldHighView Rating Details
12/15/2017AegisReiterated RatingBuyLowView Rating Details
12/5/2017HC WainwrightSet Price TargetBuy$10.00LowView Rating Details
12/5/2017B. RileySet Price TargetBuy$11.00LowView Rating Details
5/31/2017FBR & CoReiterated RatingBuyLowView Rating Details
1/3/2017Feltl & Co.Reiterated RatingStrong-BuyN/AView Rating Details
11/1/2016Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$7.50N/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Kindred Biosciences (NASDAQ:KIN) Earnings History and Estimates Chart

Earnings by Quarter for Kindred Biosciences (NASDAQ:KIN)

Kindred Biosciences (NASDAQ KIN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018($0.33)N/AView Earnings Details
11/7/2017Q3 2017($0.33)($0.29)ViewN/AView Earnings Details
8/7/2017Q2 2017($0.33)($0.29)ViewListenView Earnings Details
5/4/2017Q1 2017($0.34)($0.30)ViewListenView Earnings Details
3/1/2017Q416($0.36)($0.29)ViewListenView Earnings Details
11/7/2016Q316($0.36)($0.29)ViewListenView Earnings Details
8/8/2016Q216($0.32)($0.25)ViewN/AView Earnings Details
5/5/2016Q1 2016($0.28)($0.31)ViewN/AView Earnings Details
3/2/2016Q415($0.44)($0.32)ViewN/AView Earnings Details
11/9/2015Q3 2015($0.44)($0.36)ViewN/AView Earnings Details
8/10/2015Q2($0.42)($0.35)ViewN/AView Earnings Details
5/8/2015Q115($0.40)($0.34)ViewN/AView Earnings Details
3/12/2015Q414($0.40)($0.34)ViewN/AView Earnings Details
11/13/2014Q3 2014($0.43)($0.31)ViewN/AView Earnings Details
8/13/2014Q2 2014($0.35)($0.42)ViewN/AView Earnings Details
5/12/2014Q1 14($0.18)($0.38)ViewN/AView Earnings Details
3/6/2014($0.21)($0.40)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Kindred Biosciences (NASDAQ:KIN) Earnings Estimates

2018 EPS Consensus Estimate: ($1.38)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.32)($0.32)($0.32)
Q2 20181($0.36)($0.36)($0.36)
Q3 20181($0.35)($0.35)($0.35)
Q4 20181($0.35)($0.35)($0.35)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Kindred Biosciences (NASDAQ:KIN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Kindred Biosciences (NASDAQ KIN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 19.10%
Institutional Ownership Percentage: 66.61%
Insider Trades by Quarter for Kindred Biosciences (NASDAQ:KIN)
Institutional Ownership by Quarter for Kindred Biosciences (NASDAQ:KIN)

Kindred Biosciences (NASDAQ KIN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/2/2018Raymond TownsendDirectorSell6,419$9.45$60,659.5518,419View SEC Filing  
7/12/2017Park West Asset Management LlcMajor ShareholderBuy600,000$7.50$4,500,000.00View SEC Filing  
7/3/2017Richard ChinInsiderSell13,000$8.26$107,380.002,297,546View SEC Filing  
6/22/2017Richard ChinInsiderSell13,000$7.75$100,750.002,310,546View SEC Filing  
6/8/2017Park West Asset Management LlcMajor ShareholderBuy15,311$6.65$101,818.15View SEC Filing  
5/11/2017Park West Asset Management LlcMajor ShareholderBuy155,076$6.83$1,059,169.08View SEC Filing  
3/15/2017Park West Asset Management LlcMajor ShareholderBuy400,000$6.60$2,640,000.00View SEC Filing  
3/13/2017Park West Asset Management LlcMajor ShareholderBuy4,200$6.20$26,040.00View SEC Filing  
3/9/2017Park West Asset Management LlcMajor ShareholderBuy18,066$6.08$109,841.28View SEC Filing  
1/13/2017Park West Asset Management LlcMajor ShareholderBuy1,690,000$6.20$10,478,000.00View SEC Filing  
1/9/2017Park West Asset Management LlcMajor ShareholderBuy131,500$5.30$696,950.00View SEC Filing  
1/6/2017Park West Asset Management LlcMajor ShareholderBuy110,617$5.10$564,146.70View SEC Filing  
12/16/2016Park West Asset Management LlcInsiderSell18,000$4.78$86,040.00View SEC Filing  
12/14/2016Park West Asset Management LlcMajor ShareholderBuy8,334$4.75$39,586.50View SEC Filing  
12/13/2016Park West Asset Management LlcMajor ShareholderBuy1,148$4.75$5,453.00View SEC Filing  
12/12/2016Park West Asset Management LlcMajor ShareholderBuy3,112$4.74$14,750.88View SEC Filing  
3/15/2016Ernest MarioDirectorBuy30,000$3.55$106,500.0099,583View SEC Filing  
11/23/2015Raymond TownsendDirectorBuy2,000$4.00$8,000.0012,000View SEC Filing  
11/18/2015Raymond TownsendDirectorBuy2,323$4.78$11,103.9410,000View SEC Filing  
8/31/2015Raymond TownsendDirectorBuy1,677$5.85$9,810.457,677View SEC Filing  
8/14/2015Raymond TownsendDirectorBuy3,000$6.04$18,120.00View SEC Filing  
9/29/2014Oleg NodelmanDirectorBuy100,000$9.56$956,000.00View SEC Filing  
9/3/2014Ernest MarioDirectorBuy10,000$10.55$105,500.00View SEC Filing  
8/28/2014Oleg NodelmanDirectorBuy47,000$10.85$509,950.00View SEC Filing  
8/26/2014Oleg NodelmanDirectorBuy85,244$10.50$895,062.00View SEC Filing  
12/12/2013Kevin SchultzInsiderBuy4,000$7.00$28,000.00View SEC Filing  
12/12/2013Oleg NodelmanDirectorBuy400,000$7.00$2,800,000.00View SEC Filing  
12/12/2013Stephen SundlofSVPBuy1,000$7.00$7,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Kindred Biosciences (NASDAQ KIN) News Headlines

Source:
DateHeadline
Kindred Biosciences (KIN) Scheduled to Post Earnings on TuesdayKindred Biosciences (KIN) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - February 20 at 4:12 AM
 Brokerages Expect Kindred Biosciences Inc (KIN) to Post -$0.33 EPS Brokerages Expect Kindred Biosciences Inc (KIN) to Post -$0.33 EPS
www.americanbankingnews.com - February 17 at 3:18 PM
Kindred Biosciences to Announce Fourth Quarter and Year-End 2017 Financial ResultsKindred Biosciences to Announce Fourth Quarter and Year-End 2017 Financial Results
finance.yahoo.com - February 15 at 8:54 AM
Kindred Biosciences to Participate in the Bank of America Merrill Lynch Animal Health SummitKindred Biosciences to Participate in the Bank of America Merrill Lynch Animal Health Summit
finance.yahoo.com - February 13 at 9:00 AM
Reviewing Aduro BioTech (ADRO) and Kindred Biosciences (KIN)Reviewing Aduro BioTech (ADRO) and Kindred Biosciences (KIN)
www.americanbankingnews.com - February 5 at 11:16 AM
Kindred Biosciences (KIN) Upgraded to "Hold" at ValuEngineKindred Biosciences (KIN) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - February 5 at 12:58 AM
Reviewing G1 Therapeutics (GTHX) and Kindred Biosciences (KIN)Reviewing G1 Therapeutics (GTHX) and Kindred Biosciences (KIN)
www.americanbankingnews.com - January 31 at 11:12 PM
-$0.33 EPS Expected for Kindred Biosciences Inc (KIN) This Quarter-$0.33 EPS Expected for Kindred Biosciences Inc (KIN) This Quarter
www.americanbankingnews.com - January 31 at 5:12 PM
Kindred Biosciences Inc (KIN) Receives Average Rating of "Hold" from AnalystsKindred Biosciences Inc (KIN) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - January 30 at 7:30 PM
Kindred Biosciences (KIN) Upgraded by Zacks Investment Research to "Hold"Kindred Biosciences (KIN) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - January 13 at 6:28 PM
Kindred Biosciences Inc (KIN) Receives Consensus Rating of "Hold" from BrokeragesKindred Biosciences Inc (KIN) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - January 5 at 7:26 PM
Raymond Townsend Sells 6,419 Shares of Kindred Biosciences Inc (KIN) StockRaymond Townsend Sells 6,419 Shares of Kindred Biosciences Inc (KIN) Stock
www.americanbankingnews.com - January 4 at 9:50 PM
Kindred Biosciences (KIN) Research Coverage Started at CL KingKindred Biosciences (KIN) Research Coverage Started at CL King
www.americanbankingnews.com - December 27 at 8:09 AM
Kindred Biosciences (KIN) Given "Hold" Rating at BMO Capital MarketsKindred Biosciences (KIN) Given "Hold" Rating at BMO Capital Markets
www.americanbankingnews.com - December 25 at 1:32 PM
BRIEF-KindredBio Announces Submission Of European Medicines Agency Filing For MiratazBRIEF-KindredBio Announces Submission Of European Medicines Agency Filing For Mirataz
www.reuters.com - December 21 at 11:30 AM
Kindred Biosciences (KIN) Reports Submission of European Medicines Agency Filing for MiratazKindred Biosciences (KIN) Reports Submission of European Medicines Agency Filing for Mirataz
www.streetinsider.com - December 21 at 11:30 AM
Kindred Biosciences (KIN) Rating Reiterated by AegisKindred Biosciences (KIN) Rating Reiterated by Aegis
www.americanbankingnews.com - December 19 at 8:18 AM
Kindred Biosciences Inc (KIN) Given Consensus Rating of "Buy" by AnalystsKindred Biosciences Inc (KIN) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - December 11 at 9:52 PM
Zacks: Analysts Expect Kindred Biosciences Inc (KIN) to Post -$0.33 EPSZacks: Analysts Expect Kindred Biosciences Inc (KIN) to Post -$0.33 EPS
www.americanbankingnews.com - December 11 at 5:26 PM
Kindred Biosciences (KIN) Given a $11.00 Price Target at B. RileyKindred Biosciences (KIN) Given a $11.00 Price Target at B. Riley
www.americanbankingnews.com - December 5 at 11:22 AM
Kindred Biosciences (KIN) Given a $10.00 Price Target by HC Wainwright AnalystsKindred Biosciences (KIN) Given a $10.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - December 5 at 10:34 AM
BRIEF-KindredBio Announces Positive Results From Pivotal Study Of Zimeta OralBRIEF-KindredBio Announces Positive Results From Pivotal Study Of Zimeta Oral
www.reuters.com - December 4 at 11:57 AM
KindredBio Announces Positive Results from Pivotal Study of Zimeta Oral for Fever in HorsesKindredBio Announces Positive Results from Pivotal Study of Zimeta Oral for Fever in Horses
finance.yahoo.com - December 4 at 11:57 AM
Kindred Biosciences (KIN) Rating Increased to Hold at ValuEngineKindred Biosciences (KIN) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - December 3 at 9:36 AM
Kindred Biosciences, Inc. (KIN) Expected to Earn FY2017 Earnings of ($1.16) Per ShareKindred Biosciences, Inc. (KIN) Expected to Earn FY2017 Earnings of ($1.16) Per Share
www.americanbankingnews.com - November 22 at 6:22 AM
B. Riley Begins Coverage on Kindred Biosciences, Inc. (KIN)B. Riley Begins Coverage on Kindred Biosciences, Inc. (KIN)
www.americanbankingnews.com - November 20 at 7:40 AM
Kindred Biosciences, Inc. (KIN) Coverage Initiated by Analysts at HC WainwrightKindred Biosciences, Inc. (KIN) Coverage Initiated by Analysts at HC Wainwright
www.americanbankingnews.com - November 18 at 11:38 AM
Kindred Biosciences, Inc. (KIN) Given Consensus Rating of "Buy" by AnalystsKindred Biosciences, Inc. (KIN) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - November 16 at 7:50 PM
Edited Transcript of KIN earnings conference call or presentation 7-Nov-17 9:30pm GMTEdited Transcript of KIN earnings conference call or presentation 7-Nov-17 9:30pm GMT
finance.yahoo.com - November 13 at 11:02 AM
Kindred Biosciences, Inc. (KIN) Issues Quarterly  Earnings ResultsKindred Biosciences, Inc. (KIN) Issues Quarterly Earnings Results
www.americanbankingnews.com - November 8 at 7:11 PM
Kindred Biosciences Announces Third Quarter 2017 Financial ResultsKindred Biosciences Announces Third Quarter 2017 Financial Results
www.bizjournals.com - November 8 at 11:27 AM
Kindred Biosciences, Inc. (KIN) Expected to Announce Earnings of -$0.33 Per ShareKindred Biosciences, Inc. (KIN) Expected to Announce Earnings of -$0.33 Per Share
www.americanbankingnews.com - November 4 at 5:24 PM
Kindred Biosciences, Inc. (KIN) Set to Announce Earnings on TuesdayKindred Biosciences, Inc. (KIN) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - October 31 at 11:58 AM
Kindred Biosciences, Inc. (KIN) Receives Consensus Recommendation of "Buy" from BrokeragesKindred Biosciences, Inc. (KIN) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - October 22 at 8:38 PM
Kindred Biosciences to Announce Third Quarter 2017 Financial ResultsKindred Biosciences to Announce Third Quarter 2017 Financial Results
finance.yahoo.com - October 11 at 5:05 PM
Contrasting Kindred Biosciences (KIN) & Pain Therapeutics (PTIE)Contrasting Kindred Biosciences (KIN) & Pain Therapeutics (PTIE)
www.americanbankingnews.com - October 6 at 4:10 PM
Kindred Biosciences to Participate in the Oppenheimer & Co. Specialty Pharmaceuticals ConferenceKindred Biosciences to Participate in the Oppenheimer & Co. Specialty Pharmaceuticals Conference
finance.yahoo.com - October 6 at 2:37 AM
Head-To-Head Analysis: Spark Therapeutics (ONCE) & Kindred Biosciences (KIN)Head-To-Head Analysis: Spark Therapeutics (ONCE) & Kindred Biosciences (KIN)
www.americanbankingnews.com - October 1 at 2:32 AM
Kindred Biosciences, Inc. (KIN) Receives Consensus Recommendation of "Buy" from AnalystsKindred Biosciences, Inc. (KIN) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - September 27 at 8:44 PM
Kindred Biosciences (KIN) Presents At Ladenburg Thalmann 2017 Healthcare Conference - SlideshowKindred Biosciences (KIN) Presents At Ladenburg Thalmann 2017 Healthcare Conference - Slideshow
seekingalpha.com - September 27 at 4:17 PM
Comparing Kindred Biosciences (KIN) and Its PeersComparing Kindred Biosciences (KIN) and Its Peers
www.americanbankingnews.com - September 20 at 8:08 AM
Kindred Biosciences Announces Plans for Promotion of Dr. Zhan and Retirement of Dr. SundlofKindred Biosciences Announces Plans for Promotion of Dr. Zhan and Retirement of Dr. Sundlof
finance.yahoo.com - September 11 at 9:35 PM
Kindred Biosciences, Inc. (KIN) Given Average Rating of "Buy" by AnalystsKindred Biosciences, Inc. (KIN) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - September 2 at 8:46 PM
Kindred Biosciences to Present at Upcoming Investor ConferencesKindred Biosciences to Present at Upcoming Investor Conferences
finance.yahoo.com - August 31 at 6:40 AM
Kindred Biosciences, Inc. (KIN) Short Interest Down 29.0% in JulyKindred Biosciences, Inc. (KIN) Short Interest Down 29.0% in July
www.americanbankingnews.com - August 14 at 3:04 AM
Kindred Biosciences, Inc. (NASDAQ:KIN) Releases Quarterly  Earnings ResultsKindred Biosciences, Inc. (NASDAQ:KIN) Releases Quarterly Earnings Results
www.americanbankingnews.com - August 8 at 11:14 AM
Edited Transcript of KIN earnings conference call or presentation 7-Aug-17 8:30pm GMTEdited Transcript of KIN earnings conference call or presentation 7-Aug-17 8:30pm GMT
finance.yahoo.com - August 8 at 5:40 AM
Kindred Biosciences Announces Second Quarter 2017 Financial ResultsKindred Biosciences Announces Second Quarter 2017 Financial Results
finance.yahoo.com - August 7 at 7:38 PM
Kindred Biosciences Sponsors Veterinary Students to Attend the 2017 American Association of Feline Practitioners MeetingKindred Biosciences Sponsors Veterinary Students to Attend the 2017 American Association of Feline Practitioners Meeting
finance.yahoo.com - August 4 at 11:59 PM
 Brokerages Anticipate Kindred Biosciences, Inc. (KIN) Will Post Earnings of -$0.29 Per Share Brokerages Anticipate Kindred Biosciences, Inc. (KIN) Will Post Earnings of -$0.29 Per Share
www.americanbankingnews.com - August 2 at 10:14 PM

SEC Filings

Kindred Biosciences (NASDAQ:KIN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Kindred Biosciences (NASDAQ:KIN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Kindred Biosciences (NASDAQ KIN) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.